我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
157
33 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1995
进行中（未招募）
30
19.1%
已完成
70
44.6%
尚未招募
3
1.9%
招募中
18
11.5%
终止
28
17.8%
Unknown
6
3.8%
撤回
2
1.3%
暂无批准数据
- The CAPItello-281 phase 3 trial demonstrated that adding capivasertib to standard therapy prolonged radiographic progression-free survival by 7.5 months in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer. - The combination achieved a median rPFS of 33.2 months compared to 25.7 months with placebo, representing a statistically significant 19% reduction in disease progression risk. - Greater PTEN deficiency correlated with increased treatment benefit, with patients showing 100% PTEN loss experiencing the most pronounced survival improvements. - The safety profile showed manageable toxicities, with diarrhea, hyperglycemia, and rash being the most common adverse events in the capivasertib arm.
